


**BEST AVAILABLE COPY**

1711



Attorney Docket No. PPT-20479-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bjarne Due Larsen

MAR 20 2000

Serial No.: 09/341,590

Group Art Unit: to Be Decided

TECH CENTER 1600/2900

Filed: July 12, 1999

Examiner: To Be Decided

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING  
REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

RECEIVED  
FEB - 1 2000  
TC 1780 MAIL ROOM

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. PTO 1449 Form
3. References
4. Copy of International Search Report

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Asst. Commissioner for Patents  
Washington, DC 20231

on January 19, 2000.

Cheryl H. Agris  
(name of person mailing paper)

Cheryl H. Agris  
(signature of person mailing paper)

**BEST AVAILABLE COPY**

Attorney Docket No.: PPT-20479-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bjarne Due Larsen

Serial No.: 09/341,590

Group Art Unit: to Be Decided

Filed: July 12, 1999

Examiner: To Be Decided

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A  
REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.



RECEIVED  
FEB - 1 2000  
C 1700 MAIL ROOM

The references are as follows:


- 1) WO 98/52614
- 2) WO 98/28427
- \*3) WO 98/22577
- \*4) WO 98/11126
- 5) WO 98/03192
- 6) Sai et al., 1998, Amer. J. Physiol. 275, G514-G520
- 7) Wakamiya et al., 1998, Bull. Chem. Soc. Jpn., 71:699-709
- 8) US Patent No. 5,652,122; 29 Jul. 1997
- 9) WO 97/24445
- 10) Thomas et al., 1997, J. Pharm. Exp. Ther. 281:817-825
- 11) Prokai, 1997, Exp. Opin. Ther. Patents 7(3): 233-245
- 12) Tamai et al., 1997, J. Pharm. Exp. Ther 280:410-415
- 13) US Patent No. 5,545,719; 13 Aug. 1996
- 14) Tamai et al., 1996, Adv. Drug Delivery Rev. 19:401-424
- 15) Greene et al., 1996, J. Pharm. Exp. Ther. 277:1366-1375
- \*16) WO 95/13085
- 17) Fawell et al., 1994, Proc. Natl. Acad. Sci. USA 91:664-668
- \*18) WO 91/19735
- 19) Zhou et al., 1991, Intl. J. Pharm. 75:97-115
- 20) US Patent No. 4,847,240; 11 Jul. 1989.
- 21) US Patent No. 4,724,229; 9 Feb. 1988.

22) US Patent No. 4,542,124; 17 Sep. 1985.

An International Search Report has been issued in the corresponding PCT application, PCT/DK99/00118, a copy of which is enclosed. References cited in the International Search Report are asterisked. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: 1/19/00

  
Cheryl H. Agris, Ph.D.  
Reg. No. 34,086  
Attorney at Law  
P.O. Box 806  
Pelham, N.Y. 10803  
(914) 712-0093